The European Society for Medical Oncology (ESMO) has awarded the ESMO Immuno-Oncology Prize to Dr Ignacio Melero, Kidani Professor of Immuno-Therapeutics at the University of Oxford, in recognition of his major contributions to immuno-oncology over recent decades.
Scientists at the Centre for Medicines Discovery, part of Oxford University\u2019s Nuffield Department of Medicine, have developed a biosensor that, for the first time, allows researchers to directly measure how experimental cancer drugs engage their target inside living cells dependent on co-factors and metabolites.
Infectious diseases such as malaria, dengue, and tuberculosis are considered to pose as great a challenge to global health as new or emerging pathogens, according to a major international study led by The Global Health Network at Oxford\u2019s Nuffield Department of Medicine and commissioned by Wellcome.
A major new study led by the University of Oxford and global partners has exposed significant global blind spots in genomic surveillance of antimicrobial resistance (AMR), warning that large parts of the world lack the data needed to track and respond to emerging threats.
Professor Richard White , a professor in genetics in the Oxford Branch of the Ludwig Institute for Cancer Research, Nuffield Department of Medicine, has been awarded an Academy of Medical Sciences (AMS) Professorship.
Professor Rose McGready, Deputy Director of the Shoklo Malaria Research Unit (SMRU), part of the MORU Tropical Health Network within Oxford\u2019s Nuffield Department of Medicine, has been honoured with the 2026 ACT Australian of the Year Award. The award recognises her extraordinary three decades of service to displaced and marginalised communities along the Thai-Myanmar border, and her clinical and research, that has saved the lives of countless mothers and babies while shaping global standards of care.
Professor Tim Elliott and colleagues from Oxford Cancer and the Centre for Immuno-Oncology welcomed the Brazilian Minister of Health and senior officials for an official visit organised by the British Embassy in Brazil. The delegation met to exchange insights on cancer research, regulation, and public health, with discussions focusing on prevention, early diagnosis, and innovative treatments such as mRNA vaccines and immunotherapy.
The Society for Immunotherapy of Cancer (SITC) has honoured Dr Ignacio (Nacho) Melero, Professor of Immunotherapy at NDM's Centre for Immuno-Oncology at Oxford, for his pioneering research transforming cancer treatment through immunotherapy.
A team led by Professor Kilian Huber, Centre for Medicines Discovery, at Oxford's Nuffield Department of Medicine, has uncovered a previously unknown \u2018handbrake\u2019 mechanism controlling how cells respond to cancer drugs, reshaping global understanding of cell metabolism and drug resistance.
An innovative online treatment for childhood anxiety developed at the University of Oxford is to be adapted and tested internationally, supported by the Nuffield Department of Medicine\u2019s Global Health Network.
A new partnership between Alice\u2019s Arc, the Centre for Immuno-Oncology in the Nuffield Department of Medicine and the Sir William Dunn School of Pathology will pioneer the development of a bespoke mRNA vaccine to improve treatment outcomes for children with rhabdomyosarcoma, a rare and aggressive form of soft tissue cancer.
A new study, led by researchers at the CAMS Oxford Institute in the Nuffield Department of Medicine and TIDU in the MRC Weatherall Institute of Molecular Medicine, has found that dominant T cell responses years after infection are associated with mild COVID-19 disease, and likely play important protective roles to following viral infections.
Centre for Medicines Discovery researchers, in partnership with the COVID Moonshot initiative and the AI-driven Structure-enabled Antiviral Platform (ASAP), have developed the first open-science coronavirus antiviral. This has been formally nominated as a broad-spectrum pre-clinical drug candidate by the Drugs for Neglected Diseases initiative (DNDi).
The University of Oxford has announced a gift of \u00a310 million from the Bukhman Foundation to support ground-breaking research into type 1 diabetes. This generous funding will establish the Bukhman Centre for Research Excellence in Type 1 Diabetes, as well as create new academic posts and scholarships, helping to accelerate progress towards better treatments and ultimately a cure.
Two research teams in the Nuffield Department of Medicine have been selected for the final stages of the Cancer Grand Challenges. This includes Professor Xin Lu at Ludwig Oxford in the Cancer Antibody Atlas team and Dr Ricardo Fernandes at the CAMS Oxford Institute as a co-investigator in a team led by the Weizmann Institute.
Dr. Yi-Ling Chen, COI Career Development Fellow, awarded a prestigious ERC Starting Grant to Investigate the Role of CD1c-reactive T Cells in Post-streptococcal Disease. The ERC Starting Grant supports early-career researchers with 2-7 years of experience since completion of their PhD, providing up to \u20ac1.5 million over five years to establish independent research teams and pursue high-risk, high-reward science.
Two new papers from scientists in the Nuffield Department of Medicine and other University of Oxford institutions have shown how the immune system reacts differently depending on the length of interval between vaccine doses.
A new study published in Nature reveals that the mechanical environment surrounding a tumour can cause cancer cells to change their behaviour, triggering a switch from rapid growth to a more invasive, drug-resistant state.
A research team in the Nuffield Department of Medicine has been awarded access to one of the UK\u2019s most powerful AI supercomputing facilities to advance cancer vaccine research.
![\"\"](\"https://www.ndm.ox.ac.uk/news/advancing-cancer-care-dr-ignacio-melero-awarded-esmo-prize-for-immunotherapy-innovation/responsive_image?ratio=r16x9&scale=w760\")
\n \n \n\n\n